Breast Cancer

Tucatinib significantly improved median PFS in the overall population and those with brain metastases.

pCR rates improve regardless of whether patients received full chemotherapy doses.

Trastuzumab deruxtecan and elacestrant represent important new treatment options.

No established standard of care currently exists after spread to the lymph nodes.

The combination resulted in numerically longer OS compared with an NSAI alone.

The candidate has already demonstrated anti-tumor activity in chemotherapy-naïve patients.

A risk-stratification screening approach that considers screening at an earlier age based on risk factors might increase the likelihood of catching the cancer before it turns symptomatic.

A recent study sheds light on an alarming number of hormone-disrupting chemicals that are found in everyday settings.

Patients should work with clinicians to discuss controlled ovarian stimulation because there is still limited research.

This RNA type might act as an onco-suppressor, and higher levels may indicate better prognosis.

Significant study results could inform clinical practice strategies.

2023 was an impactful year for the field of oncology pharmacy.

The separation between those who travel for care compared to those who go to the local hospital may drive inequalities in health care.

The therapy sustained IDFS benefit compared with ET alone.

There is a prognostic impact of clinical and immunohistochemistry markers.

Almost 80% of patients have now stopped treatment with ribociclib, but benefit persists and is greater than it was 6 months ago, according to the presenter.

Study results indicate insignificant differences between PFS and OS in patients with HR[+]/HER2[-] breast cancer who received either palbociclib-letrozole or palbociclib-fulvestrant treatment.

In an interview at the 2023 San Antonio Breast Cancer Symposium, Ana Ferrigno Guajardo, MD, discussed research into the safety and efficacy of taxane-based chemotherapy use in pregnant patients with breast cancer.

As the use of sequencing, proteomics, and immunopeptidomics increases, more targets will also be discovered, as well as more biomarkers that predict responses to treatments.

Gabriel N. Hortobagyi, MD, MACP, FASCO, a professor at the University of Texas MD Anderson Cancer Center, discussed the final data on invasive disease-free survival from the NATALEE trial of ribociclib in combination with a nonsteroid aromatase inhibitor (NSAI).

Mara Hofherr, PharmD, a clinical oncology pharmacist at Washington University, highlights key findings of the KEYNOTE-522 trial in comparison of outcomes between Black and White patients with triple-negative breast cancer.

Gabriel Hortobagyi, MD, FACP, professor and chair emeritus of the Department of Breast Medical Oncology at the University of Texas MD Anderson Cancer Center discusses the changes in breast cancer management over the past decade.

Amelie G. Ramirez, DrPH, MPH, director of the Institute for Health Promotion Research at UT Health Science Center San Antonio, discussed the need for standardized questionnaires for clinicians to discuss social determinants of health with their oncology patients.

The discussion delves into the results and implications of the clinical trials, shedding light on the efficacy and safety profile of this combination therapy.

Improvements in PFS were also seen among patients with brain metastases.

pCR rates were improved with the addition of pembrolizumab regardless of whether patients received the full chemotherapy doses.

MONARCH 3 final OS data show that the combination of abemaciclib and a NSAI in the first-line resulted in numerically longer OS compared to an NSAI alone.

Individuals with HR+ breast cancer could pause endocrine therapy for up to 2 years to become pregnant, without increasing the risk of recurrence.

Patients with an estrogen receptor measure greater than 8% and those with little to no TIL expression showed no benefit with the addition of nivolumab.

Carly Giavatto, PharmD, discusses the CPS conducted study that highlights a first of its kind linkage to care initiative performed by health systems specialty pharmacists.